The former head of the FDA on Tuesday criticized the Trump administration’s efforts to lay off recently hired employees who review the safety of medical devices and other products.
The federal government said it 'ran afoul of no statute' when it announced a 15% cap on indirect cost reimbursements for NIH ...
A judge in Singapore ordered the freezing of KBP Biosciences’ assets while Novo Nordisk pursues $830 million in damages over claims that it was deceived in a 2023 licensing deal.
Siegfried’s stock dipped by 6% on the Swiss stock exchange Tuesday after reporting a lower-than-expected sales forecast for ...
Trump administration establishes Make America Healthy Again commission, fires HHS workers including FDA/CMS staff. FDA AI division hit by cuts.
Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over the weekend and picked a dose to move ...
Septerna halts Phase 1 trial of SEP-786 for hypoparathyroidism due to safety concerns, FDA approves Sanofi's Merilog insulin biosimilar, plus updates from Basilea and TME Pharma ...
A month after Biogen signaled plans to shift its attention to “ external opportunities ,” it delivered on that ...
Hikma Pharmaceuticals is asking the US Supreme Court to review a generic drug labeling ruling that it says will ...
Subsense, a startup building noninvasive technology to communicate with the brain, is launching with $17 million in funding.
AlgoTherapeutix’s topical non-opioid drug has flunked a mid-stage trial in chemotherapy-induced pain due to a ...
FDA approves Ono Pharmaceutical's Romvimza for TGCT, meaning it will compete with Daiichi Sankyo's Turalio. Drug shows better safety profile and twice-weekly dosing vs twice-daily Turalio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback